MX2021007504A - Esteroides neuroactivos alfa.-hidroxi-17.beta.-amida y composiciones de los mismos. - Google Patents

Esteroides neuroactivos alfa.-hidroxi-17.beta.-amida y composiciones de los mismos.

Info

Publication number
MX2021007504A
MX2021007504A MX2021007504A MX2021007504A MX2021007504A MX 2021007504 A MX2021007504 A MX 2021007504A MX 2021007504 A MX2021007504 A MX 2021007504A MX 2021007504 A MX2021007504 A MX 2021007504A MX 2021007504 A MX2021007504 A MX 2021007504A
Authority
MX
Mexico
Prior art keywords
sup
amide
beta
alpha
hydroxy
Prior art date
Application number
MX2021007504A
Other languages
English (en)
Inventor
Francesco G Salituro
Maria Jesus Blanco-Pillado
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Publication of MX2021007504A publication Critical patent/MX2021007504A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0066—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by a carbon atom forming part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/008—Ketals at position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
    • C07J7/007—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified not substituted in position 17 alfa

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

En este documento se proporciona un compuesto de la Fórmula (I) (ver Fórmula) (I) o una sal farmacéuticamente aceptable del mismo, en donde R2a, R2b, R4a, R4b, R6, R7, R11a, R11b, R16, R17, R3, R5, R19, RX y RY se definen en este documento. También se proporcionan en este documento composiciones farmacéuticas que comprenden un compuesto de la Fórmula (I) y métodos de uso de los compuestos, por ejemplo, en el tratamiento de trastornos relacionados con el SNC.
MX2021007504A 2018-12-21 2019-12-20 Esteroides neuroactivos alfa.-hidroxi-17.beta.-amida y composiciones de los mismos. MX2021007504A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862784222P 2018-12-21 2018-12-21
US201862784229P 2018-12-21 2018-12-21
PCT/US2019/067953 WO2020132504A1 (en) 2018-12-21 2019-12-20 3.alpha.-hydroxy-17.beta.-amide neuroactive steroids and compositions thereof

Publications (1)

Publication Number Publication Date
MX2021007504A true MX2021007504A (es) 2021-10-13

Family

ID=69591712

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021007504A MX2021007504A (es) 2018-12-21 2019-12-20 Esteroides neuroactivos alfa.-hidroxi-17.beta.-amida y composiciones de los mismos.

Country Status (12)

Country Link
US (1) US20220372067A1 (es)
EP (1) EP3898646A1 (es)
JP (1) JP2022514385A (es)
KR (1) KR20210107050A (es)
CN (1) CN113195512A (es)
AU (1) AU2019403415A1 (es)
BR (1) BR112021012242A2 (es)
CA (1) CA3124371A1 (es)
IL (1) IL284183A (es)
MX (1) MX2021007504A (es)
TW (1) TW202038967A (es)
WO (1) WO2020132504A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014018110B1 (pt) 2012-01-23 2022-06-07 Sage Therapeutics, Inc Composições farmacêutica aquosas formuladas para administração parenteral e uso de alopregnanolona e sulfobutiléter-b-ciclodextrina
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
PT3224269T (pt) 2014-11-27 2020-06-01 Sage Therapeutics Inc Composições e métodos para tratamento de distúrbios do snc
CN115974954A (zh) 2016-08-23 2023-04-18 萨奇治疗股份有限公司 19-去甲c3,3-二取代的c21-n-吡唑基类固醇的晶体
MA51046A (fr) 2017-12-08 2021-03-17 Sage Therapeutics Inc Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
CA2852057C (en) 2011-10-14 2022-06-07 Sage Therapeutics, Inc. 3,3-disubstituted 19-nor pregnane compounds, compositions, and uses thereof for the treatment of cns related disorders
KR102612943B1 (ko) 2014-10-16 2023-12-13 세이지 테라퓨틱스, 인크. Cns 장애의 치료를 위한 조성물 및 방법
US10329320B2 (en) 2015-02-20 2019-06-25 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
EP4302764A2 (en) 2016-07-11 2024-01-10 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use

Also Published As

Publication number Publication date
AU2019403415A1 (en) 2021-07-08
BR112021012242A2 (pt) 2021-09-28
KR20210107050A (ko) 2021-08-31
CA3124371A1 (en) 2020-06-25
US20220372067A1 (en) 2022-11-24
EP3898646A1 (en) 2021-10-27
TW202038967A (zh) 2020-11-01
WO2020132504A1 (en) 2020-06-25
JP2022514385A (ja) 2022-02-10
CN113195512A (zh) 2021-07-30
IL284183A (en) 2021-08-31

Similar Documents

Publication Publication Date Title
MX2021007504A (es) Esteroides neuroactivos alfa.-hidroxi-17.beta.-amida y composiciones de los mismos.
CR20210629A (es) Esteroides neuroactivos y composiciones de estos
MX2021000887A (es) Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
MX2022008066A (es) Compuestos triciclicos sustituidos.
MX2022006475A (es) Compuestos triciclicos sustituidos.
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
WO2020257549A3 (en) Compounds for treatment of pd-l1 diseases
MX2023002004A (es) Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central.
MX2020001717A (es) Inhibidores macrociclicos de mcl-1 y metodos de uso.
EP4241772A3 (en) Process for the preparation of compounds useful for treating spinal muscular atrophy
MX2023005099A (es) Composiciones y usos de las mismas para el tratamiento de trastornos en el sistema nervioso central.
MX2020001719A (es) Inhibidores macrocíclicos de mcl-1 y metodos de uso.
WO2016134301A3 (en) Neuroactive steroids, compositions, and uses thereof
EP3693369A3 (en) Bromodomain inhibitors
JP2015537020A5 (es)
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
WO2019165043A3 (en) Indane-amines as pd-l1 antagonists
MX2022016343A (es) Esteroides neuroactivos y composiciones de estos.
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
MX2022004450A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1.
MX2021004856A (es) Sulfonamida sustituida con trifluorometilo como inhibidor selectivo de bcl-2.
PH12019502150A1 (en) Compounds and methods for the treatment of parasitic diseases
MX2022006470A (es) Tiromimeticos novedosos.
EP4321519A3 (en) Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders
MX2021012105A (es) Compuestos de pirrol.